Altogether, this data indicates a strong capacity of TAK-659 to block the microenvironment-derived survival signals and a higher efficacy in co-cultured and BCR-stimulated CLL cells compared to cells in suspension. Here, CDK9 is linked to B-cell chronic lymphocytic leukemia.